Stanford University
The purpose of this study is to explore the use of digital health technology for measuring symptoms and daily health in people with primary biliary cholangitis (PBC). Biometric data captured with a wearable device will be compared to questionnaire responses (patient-reported outcomes, or PROs) and laboratory test results to test the hypothesis that changes in biometrics can be correlated to changes in disease activity.
Patients enrolled are intended to start a second-line therapy (2L) for control of their PBC - the choice of therapy will be at the discretion of the treating hepatologist. Once 2L therapy is initiated, the study will assess for correlations between changes in biochemistries (alkaline phosphatase, or ALP) with biometrics and PRO results.
* Inclusion Criteria: 1. PBC diagnosis based on meeting 2 of 3 criteria: 1. Cholestatic liver biochemistry at disease outset (defined as elevation in the serum ALP level or GGT). 2. Associated autoantibody (AMA or PBC-associated antinuclear antibody by immune fluorescence or anti-PDC, anti-Gp210, or anti-Sp100) at a titer of greater than or equal to 1:40. 3. Diagnostic or compatible liver biopsy. 2. Ability to provide informed consent 3. Ability to complete digital questionnaires 4. Elevated alkaline phosphatase * Abbreviations: alkaline phosphatase \[ALP\] gamma-glut…
Arctuva estimate
Actual pay is set by the research site.
Verify or correct the compensation shown for this listing.